Associated tags: API, CDMO, Research
Locations: US, INDIA, FRANCE, ITALY, ISRAEL, SWEDEN, PORTUGAL, SPAIN, UK, GERMANY
Pharmaceutical,
Professional Services,
Health,
Finance,
NCE,
Blue Wolf,
Patient,
CDMO,
Organization,
Parets,
OSD,
Wolf,
Pharmaceutical industry The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance.
Key Points:
- The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance.
- Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.
- “Blue Wolf is excited for the opportunity to build a new CDMO platform with these seven European assets serving as a cornerstone,” said Shashank Patel, Principal at Blue Wolf.
- I am confident that Blue Wolf will continue to elevate service excellence and bolster the organization for the benefit of customers and patients.
Retrieved on:
Tuesday, December 19, 2023
PLEASANTON, Calif., Dec. 19, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Recipharm, a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS, Veeva Vault QualityDocs, and Veeva Vault Training to streamline its quality operations. Veeva quality applications will help Recipharm achieve greater quality oversight, use resources more effectively, accelerate validation, and maintain inspection readiness.
Key Points:
- Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and manage GxP content across its organization
PLEASANTON, Calif., Dec. 19, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Recipharm , a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS , Veeva Vault QualityDocs , and Veeva Vault Training to streamline its quality operations.
- "Harmonizing quality processes and GxP documentation across Recipharm sites will make our quality operations more efficient and scalable," said Vanessa Nardolillo, head of quality management and regulatory affairs at Recipharm.
- "With Veeva Vault Quality, Recipharm is setting a new global standard for quality management, site collaboration, and compliance.
- "Unifying quality processes, content, and training on Veeva Vault Quality will help Recipharm keep contract development and manufacturing on track as it continues to scale," said Rob Gaertner, vice president of quality strategy for Europe at Veeva.
Retrieved on:
Thursday, August 17, 2023
Foam,
COPD,
Science,
Science Based Targets initiative,
Partnership,
Inhalation,
Climate,
Holmes Chapel,
Aerosol,
Sustainability reporting,
Industrial production in Shōwa Japan,
HFO,
VOC,
Carbon,
Targets,
GWP,
Chronic obstructive pulmonary disease,
Isocyanate,
Solvent,
CDMO,
Atmosphere of Earth,
Patient,
HFA,
Research Triangle Park,
ESG,
Social,
Jet fuel,
Pharmaceutical industry,
Renewable energy,
Recipharm,
Honeywell,
Environment,
Research MORRIS PLAINS, N.J. and STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.
Key Points:
- MORRIS PLAINS, N.J. and STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.
- Honeywell Solstice® Air (HFO-1234ze(E) cGMP) is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs that has 99.9% less global warming potential than HFAs.
- In addition, Honeywell Solstice Air is non-flammable, non-ozone-depleting and volatile organic compound (VOC)-exempt under federal and state guidelines.
- The partnership with Honeywell follows Recipharm's announcement that it is expanding its pMDI product development and manufacturing capabilities to accommodate increased demand from pharmaceutical companies.
Biotechnology,
Pharmaceutical,
Health,
Medical Supplies,
Multimedia,
CBO,
Messenger,
Stevanato Group,
NYSE,
Recipharm,
Safety,
Glass,
CDMO,
Use,
Inhalation,
Pharmaceutical industry Under the agreement, Stevanato Group will lend its 70+ years of manufacturing experience to support the development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Key Points:
- Under the agreement, Stevanato Group will lend its 70+ years of manufacturing experience to support the development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
- As part of this collaboration, Stevanato Group will provide and manufacture its glass pre-fillable syringe Alba® assembled with the Integrated Spray Module (ISMTM) of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler (PFSITM).
- Recipharm’s soft mist inhaler (PFSI™) is developed, manufactured, and licensed by Resyca® and is supplied as a pre-filled and ready-to-use inhalation device.
- These products require specialized, high-performance drug containment systems, like our Alba® syringe platform, together with patient-centric drug delivery devices like the PFSI™.
Retrieved on:
Monday, November 14, 2022
Lung,
API,
Marshall University,
Small Business Saturday,
Endocannabinoid system,
Partnership,
ECS,
CDMO,
Cystic fibrosis,
Degenerative disease,
SARS-COV-2,
Bronchitis,
Recipharm,
Research,
COPD,
Asthma,
Pulmonology,
Therapy,
Synthon (company),
RS,
Risk management Commenting on the partnership, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, We are very pleased to partner with Recipharm for product characterization testing to support the development of RSBT-001 as a treatment for COPD.
Key Points:
- Commenting on the partnership, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, We are very pleased to partner with Recipharm for product characterization testing to support the development of RSBT-001 as a treatment for COPD.
- Chris Hirst, Head of Recipharms Advanced Delivery Systems Business Unit said, Recipharm is delighted to be working with RS BioTherapeutics, providing product characterization testing to support the development of RSBT-001.
- In July, RS BioTherapeutics announced positive results from its proof-of-concept study with its development partner Synthonics and Marshall University, for RSBT-001.
- Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC.
Retrieved on:
Wednesday, December 30, 2020
Research,
Infectious diseases,
Clinical trials,
Cardiology,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Health sciences,
Health,
Pharmaceutical industry,
Pharmaceuticals policy,
Clinical research,
Contract manufacturing organization,
Pharmaceutical industry in China,
Clinical trial,
GenScript Biotech,
Patheon,
Moderna,
Recipharm The activity will be performed in Recipharms drug product manufacturing facility located in France.
Key Points:
- The activity will be performed in Recipharms drug product manufacturing facility located in France.
- Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it is anticipated that supply will commence in early 2021.
- Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees.
- Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.
